

Helping patients break the hold of addiction

Identifying and addressing opioid use disorder in primary care




OUD is a chronic, recurring, treatable medical condition

Nearly 6 million Americans have opioid use disorder.¹

Even though medical treatment greatly improves outcomes, only 1 in 5 people with OUD receives such treatment.²



FIGURE 1. Addiction results from physiologic changes in the brain caused by drug use, against a background of biological and environmental factors.³



Addiction to opioids can be managed with effective medications.

The goals of medications for the treatment of OUD are to:

- 1**
Relieve withdrawal symptoms
- 2**
Block effects of other opioids
- 3**
Reduce cravings
- 4**
Restore normal function

Diagnosing opioid use disorder (OUD)

According to the DSM-5, OUD is problematic opioid use that leads to significant impairment or distress.


TABLE 1. OUD is marked by at least two of the following over the past 12 months:⁴

<input type="checkbox"/>	using opioids at higher doses or longer than intended
<input type="checkbox"/>	unsuccessful attempts to control or reduce use
<input type="checkbox"/>	significant time spent obtaining, consuming, or recovering from opioids
<input type="checkbox"/>	cravings for opioids
<input type="checkbox"/>	failure to fulfill obligations because of opioid use
<input type="checkbox"/>	persistent social or interpersonal problems caused by opioids
<input type="checkbox"/>	opioid use displaces social, work, or recreational activities
<input type="checkbox"/>	using opioids in hazardous situations (e.g., while driving)
<input type="checkbox"/>	use continues despite physical or psychological problems caused or worsened by opioids
<input type="checkbox"/>	tolerance: a reduced effect of the drug despite increasing dosages (in patients taking opioids other than as prescribed)
<input type="checkbox"/>	withdrawal (in patients taking opioids other than as prescribed)

Mild: 2-3 criteria; Moderate: 4-5 criteria; Severe: 6 or more criteria

Opioid dependence does **not** equal opioid addiction.

FIGURE 2. How tolerance, dependence, and OUD differ⁵




A patient who becomes physically dependent on opioids prescribed for chronic pain or for the treatment of OUD, and takes them as prescribed with no impairment of daily life, is not considered to have an addiction.

DSM: *Diagnostic and Statistical Manual of Mental Disorders*

Managing OUD in primary care


The Substance Abuse and Mental Health Administration recommends **SBIRT** (**S**creening, **B**rief Intervention and **R**eferral to **T**reatment) to identify and manage patients who may have OUD.

FIGURE 3. Identifying patients with risky behaviors can be as easy as 1-2-3⁶



Screening for substance misuse or use disorder

Universal screening of all patients in primary care normalizes the question and gives all patients an opportunity to disclose use. **Ask a simple question to open the conversation:**



A formal tool like the **Drug Abuse Screening Test (DAST-10)** provides a format for asking about drug use and opening the conversation to gather information required to diagnose OUD.



DAST-10

Engage patients with problematic opioid use

➔ Initiate a brief intervention.

Comprised of one or more 5- to 15-minute conversations, a brief intervention can motivate the patient to change substance use patterns.

Tips for effective, collaborative brief intervention conversations:

- Ask the patient for permission to share information about problematic opioid use.
- Provide information, then elicit the patient’s own views.
- Ask if the patient would be interested in resources.
- Summarize and confirm the plan with the patient.
- Schedule follow-up, even in patients who are not ready to start treatment.

➔ Discuss overdose prevention and whole person care with all patients.

Like wearing seat belts, simple steps can help all patients reduce risks to their health.



Prescribe intranasal naloxone (e.g., Narcan) to prevent overdose



Recommend or provide immunizations
(hepatitis, pneumococcus, tetanus)



Screen for infections
(especially HIV, hepatitis C and B, and STIs like syphilis)

Other strategies:

- Discuss strategies to **prevent infections**.
- Evaluate whether **pre-exposure prophylaxis (PrEP)** is indicated for HIV prevention.
- Ask patients about **pregnancy plans** to support their goals.


➔ Use “person-first” language.

Language to avoid	Recommended language
addict, abuser, user, junkie	a person with OUD
clean/dirty urine	urine positive/negative for opioids or other substances
treatment failure	return to use, recurrence

STI: sexually transmitted infection


Effective medications can save lives

Three medications are FDA-approved to treat OUD.



Medications to treat OUD can improve retention in treatment, decrease opioid misuse, and **reduce the risk of death.**

FIGURE 4. In a randomized trial, buprenorphine kept more patients alive and engaged in treatment compared to detoxification and counseling.⁷



Medication for OUD is more effective than detoxification and abstinence-based treatment alone.⁸

Key points

- Opioid use disorder is a **chronic, treatable disease** that affects millions of Americans.
- It is defined by **problematic opioid use** that leads to **significant impairment or distress**.
- Patients with prescribed, chronic opioid use may have **tolerance and withdrawal without having or developing an addiction to opioids**.
- **Screen all primary care patients** for opioid and other substance use disorders.
- **Identify patients with OUD and initiate treatment** using SBIRT: Screening, Brief Intervention, and Referral to Treatment.
- **Ensure that naloxone (e.g., Narcan) is available** to patients with OUD and those who take high-dose opioids to prevent overdose; it can be life-saving.
- **Medications** like buprenorphine are safe and a highly effective strategy to help manage OUD for many patients.

Visit AlosaHealth.org/OUD
for links to a comprehensive evidence document and other resources.

References:

(1) Substance Abuse and Mental Health Services Administration. *Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health*. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration;2021. HHS Publication No. PEP24-07-021, NSDUH Series H-59). (2) Substance Abuse and Mental Health Services Administration. 2023 NSDUH Detailed Tables. <https://www.samhsa.gov/data/report/2023-nsduh-detailed-tables>. July 30, 2024. Accessed Oct 2, 2024. (3) National Institute on Drug Abuse. Drug misuse and addiction. <https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction>. Published July 13, 2020. Accessed February 23, 2022. (4) American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, 5th Ed., Text Revision*. Arlington, VA: American Psychiatric Publishing; 2022. (5) Szalavitz M, Rigg KK, Wakeman SE. Drug dependence is not addiction-and it matters. *Ann Med*. 2021;53(1):1989-1992. (6) Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration;2021. (7) Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet*. 2003;361(9358):662-668. (8) Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. *JAMA*. 2000;283(10):1303-1310.

Image on page 6 (medication classes): ©2016 The Pew Charitable Trusts. pewtrusts.org/-/media/assets/2016/11/medicationassistedtreatment_v3.pdf

About this publication

These are **general recommendations only**; specific medical decisions should be made by the treating clinician based on an individual patient's clinical condition. More detailed information on this topic is provided in a longer evidence document at AlosaHealth.org.



This material is provided by **Alosa Health**, a nonprofit organization which accepts no funding from any pharmaceutical company.

This material was produced by Ellie Grossman, MD, MPH, Instructor in Medicine; Benjamin N. Rome, MD, MPH, Instructor in Medicine (principal editor); Jerry Avorn, MD, Professor of Medicine; all at Harvard Medical School; and Ellen Dancel, PharmD, MPH, Director of Clinical Materials Development at Alosa Health. Drs. Avorn and Rome are physicians at the Brigham and Women's Hospital, and Dr. Grossman practices at the Cambridge Health Alliance. None of the authors accepts any personal compensation from any drug company.

This material was supported by the New Hampshire Department of Public Health. A prior version was supported by the Pharmaceutical Assistance Contract for the Elderly (PACE) Program of the Pennsylvania Department of Aging and the Office of Drug Surveillance and Misuse Prevention of the Pennsylvania Department of Health, through funding from the Centers for Disease Control and Prevention.